


### CLAIMS


1. A method of treating pain caused by inflammation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound 1:



or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof.


2. The method of claim 1, wherein the pain is caused by initiation of the inflammatory response.
3. The method of any of the foregoing claims, wherein the pain is associated with hyperalgesia.
4. The method of any of the foregoing claims, wherein the pain is chronic pain or subacute pain.
5. The method of any of the foregoing claims, wherein the chronic pain is arthritis pain, low back pain, neuropathic pain, visceral pain, pain due to cancer, pain due to injury, pain due to joint inflammation, pain due to back disorders, or neck pain.
6. The method of claim 5, wherein the pain due to cancer is caused by cancer involving intraperitoneal abdominal and pelvic organs or bone cancer or bone metastases.
7. The method of claim 5, wherein the pain due to injury is caused by bone, ligament, or tendon injury.
8. The method of any of the foregoing claims, wherein Compound 1 reduces pain to a similar degree as a central-nervous system-acting opioid.
9. The method of claim 8, wherein the central-nervous system-acting opioid activates a *mu* receptor.
10. The method of claim 8, wherein the central-nervous system-acting opioid is morphine.

11. The method of any of the foregoing claims, wherein administering Compound 1 does not result in any central-nervous system side effects.
12. The method of claim 11, wherein the central nervous system side-effects are addiction, constipation, sedation, impaired mentation, somnolence, respiratory depression, nausea, dysphoria, or seizures.
13. The method of claim 12, wherein administering Compound 1 does not result in constipation.
14. The method of claim 12, wherein administering Compound 1 does not result in addiction.
15. The method of any of the foregoing claims, wherein Compound 1 results in synergistic activation of *kappa* and *delta* opioid receptors.
16. The method of claim 16, wherein the synergy results from allosteric modulation of *kappa* receptors by *delta* receptor activity.
17. The method of any of the foregoing claims, wherein administration of Compound 1 is similar or superior to a *kappa* receptor agonist for treatment of acute pain.
18. The method of any of the foregoing claims, wherein administration of Compound 1 is similar or superior to a *kappa* receptor agonist for treatment of hyperalgesia.
19. The method of any of the foregoing claims, wherein administration of Compound 1 results in reduced urinary output compared to a *kappa* receptor agonist.
20. Use of the Compound 1:




or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof for the treatment of pain caused by inflammation or the initiation of the inflammatory response.

21. Use of the Compound 1:




or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof in the manufacture of a medicament for the treatment of pain caused by inflammation or the initiation of the inflammatory response.

22. A method of preventing pain caused by inflammation or the initiation of the inflammatory response in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound 1:




or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof.

23. Use of the Compound 1:




or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof for the prevention of pain caused by inflammation or the initiation of the inflammatory response.

24. Use of the Compound 1:



or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof in the manufacture of a medicament for the prevention of pain caused by inflammation or the initiation of the inflammatory response.

25. A pharmaceutical composition comprising Compound 1:



and a pharmaceutically acceptable carrier.